secwatch.observer — SEC 8-K summary
======================================

Issuer:     Polaryx Therapeutics, Inc. (PLYX)
CIK:        0002075320
Form:       8-K
Filed at:   2026-09-01T20:30:15+00:00
Accession:  0001213900-26-096235
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026
--------------------------------------------------------------------------------

- Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.
- Previously SVP Clinical Development at Tyra Biosciences; led Phase 2 rare disease trial; also CMO at Spruce Biosciences.
- SOTERIA Phase 2 trial of PLX-200 in CLN2, CLN3, Krabbe, Sandhoff diseases; FDA safe-to-proceed Oct 2025; initiation planned Q4 2026.
- Dr. Charlton's background includes roles at 89bio, Ascendis Pharma, Allergan; board-certified pediatric endocrinologist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/0001213900-26-096235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/ea0303928-8k_polaryx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-096235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer